Literature DB >> 28043983

Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma.

G H Teló1, G F Carvalhal2, C G S Cauduro2, V S Webber3, C H Barrios2,3,4,5, A P Fay2,3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28043983     DOI： 10.1093/annonc/mdw447

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

Review 1.  Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.

Authors:  Lisa A Kottschade
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

Review 2.  Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors:  Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

Review 3.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

4.  Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.

Authors:  Michiru Shiba; Hidefumi Inaba; Hiroyuki Ariyasu; Shintaro Kawai; Yuko Inagaki; Shohei Matsuno; Hiroshi Iwakura; Yuki Yamamoto; Masahiro Nishi; Takashi Akamizu
Journal:  Intern Med       Date:  2018-02-28       Impact factor: 1.271

5.  Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.

Authors:  Jeroen M K de Filette; Joeri J Pen; Lore Decoster; Thomas Vissers; Bert Bravenboer; Bart J Van der Auwera; Frans K Gorus; Bart O Roep; Sandrine Aspeslagh; Bart Neyns; Brigitte Velkeniers; Aan V Kharagjitsingh
Journal:  Eur J Endocrinol       Date:  2019-09       Impact factor: 6.664

6.  A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.

Authors:  Naoko Yamamoto; Yuya Tsurutani; Sho Katsuragawa; Haremaru Kubo; Takashi Sunouchi; Rei Hirose; Yoshitomo Hoshino; Masahiro Ichikawa; Tomoko Takiguchi; Hiroko Yukawa; Hitoshi Arioka; Jun Saitou; Tetsuo Nishikawa
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.